Clinical Trial: NCT05379985
Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
Status:
RECRUITINGPhase:
Phase 1| Lead Sponsor: | Revolution Medicines, Inc. |
| Information Provided By: | Revolution Medicines, Inc. |
| Last Update Posted: | 2026-05-15 |
Study Overview
Brief Summary
Evaluate the safety and tolerability of RMC-6236 in adults with specific RAS mutant advanced solid tumors.
Official Title
A Multicenter Open-Label Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
Conditions
Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Pancreatic Ductal Adenocarcinoma (PDAC), Advanced Solid Tumors
Intervention / Treatment
- Drug: RMC-6236
Other Study ID Numbers
- RMC-6236-001
Start Date (Actual)
2022-05-31
Primary Completion Date (Estimated)
2027-05-31
Study Completion Date (Estimated)
2027-07-26
Enrollment (Estimated)
754
Study Type
Interventional
Phase
Phase 1, Phase 2
| Lead Sponsor: | Revolution Medicines, Inc. |
| Information Provided By: | Revolution Medicines, Inc. |
| Last Update Posted: | 2026-05-15 |
Study Overview
Brief Summary
Evaluate the safety and tolerability of RMC-6236 in adults with specific RAS mutant advanced solid tumors.
Official Title
A Multicenter Open-Label Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
Conditions
Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Pancreatic Ductal Adenocarcinoma (PDAC), Advanced Solid Tumors
Intervention / Treatment
- Drug: RMC-6236
Other Study ID Numbers
- RMC-6236-001
Start Date (Actual)
2022-05-31
Primary Completion Date (Estimated)
2027-05-31
Study Completion Date (Estimated)
2027-07-26
Enrollment (Estimated)
754
Study Type
Interventional
Phase
Phase 1, Phase 2